Narrow Results

This study outlines a drug delivery mechanism that utilizes two independent vehicles, allowing for delivery of chemically and physically distinct agents. The mechanism was utilized to deliver a new anti-cancer combination therapy consisting of piperlongumine (PL) and TRAIL to treat PC3 prostate cancer and HCT116 colon cancer cells. PL, a small-molecule hydrophobic drug, was encapsulated in poly (lactic-co-glycolic acid) (PLGA) nanoparticles. TRAIL was chemically conjugated to the surface of liposomes. PL was first administered to sensitize cancer cells to the effects of TRAIL. PC3 and HCT116 cells had lower survival rates in vitro after receiving the dual nanoparticle therapy compared to each agent individually. In vivo testing involved a subcutaneous mouse xenograft model using NOD-SCID gamma mice and HCT116 cells. Two treatment cycles were administered over 48 hours. Higher apoptotic rates were observed for HCT116 tumor cells that received the dual nanoparticle therapy compared to individual stages of the nanoparticle therapy alone.

The Fe₃O₄ nanoparticles coated by citrate (citric acid, CA) were prepared by chemical co-precipitation method. Via Stokes polarimeter, the variation of retardance in water-based CA coated Fe₃O₄ ferrofluids (FFs) with different molarities of CA solutions was measured and compared. Next, the verification of the sample with the second high retardance using orthogonal test of L₉(3⁴) in our previous study was executed. Further, the heating performance of this CA coated FF sample with high magnetic retardance and response in the alternating magnetic field was investigated. When the concentrations of CA coated FFs were 2mg/ml and 50mg/ml, under the external alternating magnetic field with applied apparent current of 300A, after heating 76s and 16s, the temperature of the CA coated FFs is greater than 45°C, respectively, reached the requirements for the magnetic inductive heating treatment of medicinal cancer tumor.